AstraZeneca Says 2nd-Quarter Earnings Dropped 27 Percent

Sales of cancer drugs, including Lynparza and Tagrisso, rose 44 percent to $1.43 billion. That helped offset a 40 percent decline in sales of Crestor as the cholesterol treatment lost patent protection in Europe and Japan.